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ABSTRACT

TREATMENT OF HYPERTRIGLYCERIDEMIA WITH
OMEGA-3 FATTY ACIDS: A SYSTEMATIC REVIEW

Amanda Gloria Lewis
College of Nursing
Masters of Science

Purpose: To 1) critically appraise available randomized controlled trials (RTCs)
addressing the efficacy of long-chain ω-3 fatty acids as a secondary prevention agent of
hypertriglyceridemia, and 2) make recommendations for clinical practice.
Data Sources: All RCTs identified from several databases from 1993-2003 were
reviewed by two independent reviewers who extracted data from each study and used the
previously tested Boyack and Lookinland Methodological Quality Index (MQI) to
determine study quality.
Results: Ten studies reported long-chain ω-3 fatty acids to be effective in the treatment
of hypertriglyceridemia. The average decrease in triglycerides (TG) was 29%, total
cholesterol (TC) 11.6%, very low density lipoprotein (VLDL) 30.2%, and low-density
lipoprotein (LDL) 32.5%. One study found LDLs to increase by 25%. The average
increase in high-density lipoprotein (HDL) was 10%. The overall average MQI score was
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36% (26%-54%). Many of the RCTs had serious shortcomings including short duration,
lack of a power analysis, no intention to treat analysis, no report of blind assessment of
outcome, and lack of dietary control as a confounding variable.
Conclusions/Implications: Overall study methodology was weak. Although the evidence
supporting the use of long-chain ω-3 fatty acids in the secondary prevention of
hypertriglyceridemia is reasonably strong, until there are larger RCTs of stronger
methodological quality, it is not recommended to treat hypertriglyceridemia with ω-3
fatty acid supplementation in lieu of lipid lowering medications.

Key Words: Long-chain ω-3 fatty acids, eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA), hypertriglyceridemia, hyperlipidemia, systematic review, critical appraisal,
alpha linolenic acid, ω-6 fatty acids
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Coronary heart disease (CHD), the leading cause of death among men and women
of all ages, has been estimated to affect 12.4 million people in the United States
(American Heart Association [AHA], 2000; National Health and Nutrition Examination
Surveys, 2002). Identified risk factors for CHD include elevated total cholesterol (TC)
and low-density lipoprotein (LDL) levels, while a high level of high-density lipoprotein
(HDL) has been shown to be cardioprotective. High levels of triglycerides (TG) have
recently been reported as a risk factor for CHD independent of the HDL level (Fruchart
& Duriez, 2002; Gotto, 2002).
Women typically have lower TC levels than men until they reach menopause.
After menopause TC levels begin to climb until the levels actually exceed those of men
(National Health and Nutrition Examination Surveys, 2002). Recent evidence suggests
that the relative risk of cardiovascular disease for women with hypertriglyceridemia is
higher than for men (RR = 1.75 vs. 1.30). Even after accounting for HDL levels, men and
women with elevated TG have a significantly higher risk for CHD (Austin, 1998).
The combination of high TG and low HDL levels associated with insulin
resistance contribute substantially to CHD. The cluster of symptoms identified as insulin
resistance includes borderline high blood glucose levels, hypertension, increased uric acid
levels, and central obesity. If individuals with insulin resistance have a TC level
considered borderline by the National Cholesterol Education Program Adult Treatment
Panel III guidelines, they are not categorized as being at higher risk for CHD (Fruchart &
Duriez, 2002).
The goals of hyperlipidemia management remain primary and secondary
prevention of CHD. Current treatment includes diets low in saturated fat and cholesterol,
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exercise, and medications such as statins, niacin, cholesterol absorption inhibitors, bile
acid sequestrants, and a derivative of fibric acid (gemfibrozil). Beginning in the late
1970s, preliminary research suggested that long chain omega-3 (ω-3) fatty acids
prevented CHD. The two long chain ω-3 fatty acids that are thought to have
cardioprotective effects are eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). Unlike ω-6 fatty acids, EPA and DHA lower postprandial lipemia and prevent
the lowering of HDL. EPA also lowers TC and TG levels by preventing LDL and TG
synthesis in the liver (Harper & Jacobson, 2001).
Several randomized controlled trials (RCTs) and observational studies reported a
decline in TG levels when long chain ω-3 fatty acids were consumed (Harper &
Jacobson, 2001). However, questions remain regarding their use to treat mild to moderate
hypertriglyceridemia. Much of the debate centers on the effectiveness of ω-3 fatty acid
supplements as opposed to dietary intake of ω-3 fatty acids and the recommended dose of
the supplement. Therefore, the purposes of this systematic review are to evaluate the
evidence available on long chain ω-3 fatty acids in secondary prevention of
hypertriglyceridemia in otherwise healthy individuals, determine the best treatment
options, and make recommendations for clinical practice.
Methods
Identification of Studies
An electronic search was conducted to identify studies from January 1994 to
February 2003 in the following databases: EMBASE, MANTIS, Biosis Previews,
Science Search, International Pharmaceutical Abstracts, MEDLINE, PubMed, CINAHL,
and the Cochrane Library. The search terms used were: eicosapentaenoic acid, EPA,
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docosahexaenoic acid, DHA, ω-3 fatty acids, adult, human, randomized controlled trial,
hyperlipidemia, and hypertriglyceridemia. The search was limited to studies published in
English. Reference lists of identified articles were searched for additional studies that had
been missed. Nine randomized controlled trials were found that matched the search
criteria. Contact persons for each of the identified studies were sent a complete list of
studies via letter or email and were asked to identify any studies not yet published or not
included in the list. One month was allowed for a response. Six of the contacts did not
respond to the request. One additional study was identified through contact
correspondence (Mori et al., 2000). A list of excluded articles is available from the
authors by request.
Inclusion/Exclusion Criteria
For inclusion in the review study subjects must have had TG levels greater than
150 mg/dL and/or TC greater than 200 mg/dL. Studies were included if the ω-3 fatty acids
EPA and/or DHA were ingested in doses greater than or equal to 3 g/d. All types of
hyperlipidemia were included in this review because, in most instances, subjects were not
classified by type. Studies were excluded if the subjects had secondary
hypertriglyceridemia, known CHD including hypertension, a strong family history of
CHD, were part of an ethnic population associated with higher incidences of CHD, had
diabetes mellitus or fasting blood sugar levels greater than 130 mg/dL, hypothyroidism,
were smokers, alcohol abusers, used hormone replacement therapy for control of
menopausal symptoms, or used statins or gemfibrozil as treatment options.
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Data Extraction
The Boyack and Lookinland Methodological Quality Index (MQI) (Boyack,
Lookinland, & Chasson, 2002) was used to evaluate the quality of the studies included in
the review (Table 1). The tool evaluates the strength of the study’s design, methods, and
analysis. Each study was scored by two independent reviewers (A. L., and S. L.),
differences were settled, and consensus was reached by referring to the original study.
Overall inter-rater reliability was r = 0.92. In order to score an article, the information
provided in the study was compared with the MQI tool and each item was scored. The
final score for an individual study was presented as a percentage. The percentage was
found by taking the study’s total score and dividing it by the total possible score.
Some study results of lipid levels were reported in mmol/L. When this occurred,
the values in mmol/L were divided by the conversion factor 0.0259 for cholesterol values
and 0.0113 for TG values to convert the values to mg/dL to allow for the comparison of
studies (American Medical Association, 2000).
Results
Study Characteristics
A total of 10 RCTs were identified from the medical and nutritional literature.
Three of the 10 studies involved multiple sites (Borthwick, 1998; Harris et al., 1997;
Mackness et al, 1994). Although one study was conducted in the United States, most
research on ω-3 fatty acids took place in other countries (Australia, Canada, Italy,
Norway, Portugal, and the United Kingdom). All of the study designs were RCTs with
one using a crossover trial (Calabresi, Donati, Pazzucconi, Sirtori, & Franceschini, 2000).
The length of the studies ranged from 4 to 16 weeks.
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A weakness in all of the studies was a lack of a power analysis. None had a
duration longer than 16 weeks, making it difficult to determine the effectiveness of longterm treatment. None of the studies were long enough to be able to report the long-term
health outcomes of acute cardiac event prevention, but rather focused on surrogate lipid
measures.
Although all the studies reported a decrease in TG, none controlled for diet which
could be a major confounding variable if participants in the studies consumed large
amounts of ω-3 fatty acids in their diet. Only one of the studies had their participants
follow the National Cholesterol Education Program Step I diet while monitoring
compliance (Harris et al., 1997).
Quality of Studies
Each study received a quality score from the Boyack and Lookinland MQI that
ranged from 26% to 54% out of a possible 100% (Table 2). The average total MQI for the
10 studies was 36%. The higher the score the more closely it matched the standards of the
quality index and the higher its methodological soundness. No minimum score was
necessary to be included in this review.
Patient Characteristics
A total of 606 people were studied overall with 83 % being male (n = 505).
Sample sizes ranged from 14 to 234 with no ethnic minorities included. In the majority
of cases the type of hyperlipidemia was not identified. There are seven basic types of
hyperlipidemia (Table 3), including types I through V, secondary hypertriglyceridemia,
and familial lecithin cholesterol acyltransferase deficiency (Beers & Berkow, 1999).
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Treatment Characteristics
Pronova Biocare (Oslo, Norway), the manufacturer of Omacor and K-85,
provided funding for five of the six studies that used their products. Other ω- 3
preparations included those from Croda Chemicals (Laidlaw & Holub, 2003), Fish Oil
Test Materials Program (Mori et al., 2000), and Hebron (Silva et al., 1996). Dosages of
ω-3 fatty acids ranged from 3.4 - 4 g per day either as combinations of DHA and EPA or
DHA and EPA separately. One study examined the effects of DHA and EPA and varying
doses of gamma-linolenic acid (Laidlaw & Holub, 2003). Another study used a crossover
design with Omacor and thus had no placebo (Calabresi et al., 2000). The placebos used
in the remaining studies were corn oil (6), soya oil (1), and olive oil (1).
Clinical Outcomes
All studies except Silva et al. (1996) reported significant decreases in TG levels
when study participants were treated with ω-3 fatty acids in dosages of greater than 3.4 g
per day. However, participants included in Silva et al. were consuming fish meals more
than six times per week and thus had a significant dietary source of ω-3 fatty acids. The
average decrease in TG levels in the studies that found a significant change was 29%
(range = 16%-45%). In the three studies that looked at TC the average decrease was 9.3%
(Grimsgaard, Bønaa, Hansen, & Nordøy, 1997; Harris et al., 1997; Laidlaw & Holub,
2003). However, seven studies found that EPA and DHA had no significant effect on TC
levels (Borthwick, 1998; Chan et al., 2003; Goodfellow, Bellamy, Ramsey, Jones, &
Lewis, 2000; Laidlaw & Holub; Mackness et al., 1994; Mori et al., 2002; Silva et al.).
LDL decreased 11.3% in one study (Laidlaw & Holub). However, three studies found
LDL to increase significantly (Calabresi et al., 2000; Harris et al.; Mori et al.) by an
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average of 21.6% (range = 8%-32%), while others found no significant change in LDL
(Calabresi et al.; Chan et al.; Goodfellow et al.; Grimsgaard et al.; Laidlaw & Holub;
Mackness et al.; Silva et al.). Mori et al. reported an 8% rise in LDL with DHA but not
EPA. Very low density lipoprotein (VLDL) decreased by 27% (range = 18%-33%) in
five studies that used VLDL as an outcome measure (Chan et al.; Calabresi et al.;
Grimsgaard et al.; Harris et al.; Mackness et al.). Some studies reported significant
increases in HDL of 9.2% (range = 4%-13%) (Harris et al.; Grimsgaard et al.; Laidlaw &
Holub) while others found EPA and DHA had no significant effect on HDL levels
(Borthwick; Calabresi et al.; Chan et al.; Goodfellow et al.; Mackness et al.; Silva et al.)
Discussion
Although all of the studies found a significant decrease in TG, the average quality
index score of 36% indicates that the studies were of relatively low quality. However, the
average overall score to determine the effectiveness of ω-3 fatty acids in this review is
comparable to the MQI score recently reported in a study examining the effectiveness of
using garlic to treat elevated lipid levels (Alder, Lookinland, Berry, & Williams, 2003).
Many of the same methodological flaws reported by Alder et al., were seen here as well.
These included small sample sizes, a lack of a power analysis, and a lack of control for
confounding variables such as fish intake. Additionally, all of the studies were of such a
short duration (range 4-16 weeks) that it was impossible to evaluate the effectiveness of
long-term ω-3 fatty acid supplementation on hypertension and CHD prevention.
However, Harris (1996) reported that continued supplementation with ω-3 fatty acids
resulted in lowering TG even after 7 years of treatment.
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Studies would have received higher MQI scores if more information on treatment
concealment and on blind assessment of outcomes was provided and limitations and
biases were reported. None of the studies did a power analysis before undertaking the
study. Without a power analysis it would be difficult to determine if negative findings
were truly negative or whether a type II error was made. Biases can occur without
concealment of treatment since the researchers may know the study groups to which
participants were assigned.
Practitioners plan treatment options based upon findings of drug efficacy on longterm health outcomes. Although ω-3 fatty acids have been shown to decrease TG in a
primarily white male population, the question remains, are the findings generalizable to
women and ethnic minorities? On-line resources are available to calculate CHD risk
based upon TG and other known cardiac risk factors. One such risk calculator provides
an estimate of risk for developing CHD over a 10-year period (National Heart, Lung, and
Blood Institute, 2002). The tool takes into account age, gender, TC, HDL cholesterol,
smoker, and systolic blood pressure. A more inclusive risk calculator for CHD, based on
gender, age, LDL, HDL, TG, systolic blood pressure, smoking history, diabetes mellitus,
and family history of myocardial infarction calculates the risk of developing CHD over a
10 year period (International Task Force for Prevention of Coronary Heart Disease, n.d.).
These risk calculators could be used to guide the practitioner in identifying patients who
are at an increased risk of developing CHD in order to institute preventative therapies.
None of the studies addressed possible confounding variables by controlling for
diet during the study. A diet low in saturated fats and high in ω-3 fatty acids is the first
step in the treatment of patients with increased lipid levels (National Cholesterol
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Education Program Expert Panel, 2002). While it is very costly to strictly control diet
during the course of a study, it is impossible to isolate the efficacy of ω-3 fatty acids if
subjects are consuming significant amounts of dietary ω-3 fatty acids. It is important to
mention that when testing the effectiveness of ω-3 fatty acids in real life clinical
situations, the practitioner has no control over an individual patient’s diet. When
analyzing future studies evaluating the efficacy of ω-3 fatty acids, the reader must
evaluate the extent of dietary control, power analysis, intention to treat analysis, and
reporting of biases and flaws in the study.
Although the underlying mechanism of action of ω- 3 fatty acids remains
unknown, studies have shown that their effects are dose related (Carroll & Roth, 2002;
Sanders, 1991). Chan et al. (2003) postulated that ω-3 fatty acids reduce TG by lowering
the production of VLDL apolipoprotein B, thus decreasing cholesterol synthesis in the
liver. The decreased synthesis of VLDL results in a lower level in the blood and more
VLDL converted into LDL. Others (Calabresi et al., 2000) believe that ω-3 fatty acids
decrease TG by altering lipoprotein metabolism in the liver and exerting an effect on
target lipid genes. When synthesis of TG and VLDL is decreased, the breakdown of
intermediate-density lipoprotein (IDL) is also decreased and more IDL particles are
converted to LDL. However, since LDL particles are not broken down this may result in
a rise in LDL. In patients with type IV and V hyperlipidemias LDL increased as TG
decreased with ω-3 fatty acid supplementation (Calabresi et al., 2000; Sanders, 1991).
Large lipid particles, such as chylomicrons and VLDL, cannot pass through the
endothelial wall and are deposited in the blood vessel intima. Because small particles
such as small VLDL particles, VLDL remnants, and IDLs, can easily pass through the
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endothelial barrier they are considered highly atherogenic (Fruchart & Duriez, 2002). It is
known that small VLDL particles are easily converted to LDL (Sanders, 1991).
Although TG can be lowered by dietary intake of long chain ω-3 fatty acids, the
amount needed to achieve therapeutic levels depends on the type of fish consumed (Table
4). Although there are other non-fish sources of ω-3 fatty acids, studies have not
confirmed the benefits of non-fish oil sources. In the typical American diet the total
intake of ω-3 fatty acids is ≈ 1.6 g/d (Kris-Etherton, Harris, & Appel, 2002). The
majority of this (≈1.4 g/d) is in the form of α-linolenic acid, which largely comes from
canola and soybean oil. The American Heart Association recommends consuming two
fish meals per week with emphasis on fatty fish (i.e., salmon, herring, and mackerel), but
discourages fried fish because of its high trans-fatty acid and low ω-3 fatty acid content.
The World Health Organization and other countries (Canada, Sweden, United Kingdom,
Australia, and Japan) have recommended the consumption of 0.3 to 0.5 g/d of EPA and
DHA. It has been recommended that patients with CHD increase their dose to 1 g/d of
DHA and EPA (Kris-Etherton et al.).
The amount of fish needed to lower TG levels can be difficult to consume because
of the high cost of fish, the risk of environmental toxins with certain species of fish, and
the vast amounts needed to achieve a decrease in TG levels. Omega-3 fatty acid
supplements are considered a food supplement by the Food and Drug Administration, and
different preparations contain varying amounts of DHA and EPA. The most common ω-3
fatty acid supplements contain 180 mg of EPA and 120 mg of DHA in each capsule
(Kris-Etherton et al., 2002). In order for patients with CHD to consume ≈ 1g/d of DHA
and EPA three capsules per day would be needed. More concentrated preparations of

Treatment of Hypertriglyceridemia

11

DHA and EPA can be found in the European market. Omacor is one such preparation,
but it is not currently available in the United States. In 2003, Pronova Biocare, the maker
of Omacor, is applying for a new drug application with the FDA.
The efficacy of ω-3 fatty acid supplementation also depends heavily on the type
of hyperlipidemia being treated. For those with type II or III hyperlipoproteinemia, fish
oil supplements will slightly decrease TG and VLDL, and have no effect on LDL or TC
levels. In those with type IV or V, however, a significant decrease in TG will result in a
rise in LDL and little or no change in TC with possible slight or no increases in HDL
(Sanders, 1991).
Omega-6 fatty acids are the fatty acids consumed in largest amounts by most
Americans. Some of the common sources of ω-6 fatty acids are walnuts, brazil nuts,
canola, corn, evening primrose, sesame, safflower, soya, and sunflower oil (Willett,
2001). They reduce TC, decrease cholesterol deposits in vessels, and cause a slight
decrease in TG levels (Kris-Etherton, 1999). Although the majority of studies reviewed
used an ω-6 fatty acid as placebo, this was not considered a methodological flaw since
this is the major dietary source of fatty acids in the United States.
Other benefits have been associated with the intake of ω-3 fatty acids. A strong
negative relationship has been found between fish intake or supplementation and risk of
sudden death (Albert et al., 1998; Siscovick et al., 1995) and coronary heart disease
(Djousse et al., 2001). These findings have been confirmed in healthy men as well
(Albert et al., 2002). A lower risk (RR = 0.4) of acute myocardial infarction (AMI) was
reported in both sexes (Landmark et al., 1998). In those who suffered an AMI, the infarct
size was smaller (Guallar et al., 1999).
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While the current evidence suggests that supplementation of ω-3 fatty acids in
doses greater than 3.4 g in Caucasian males with hypertriglyceridemia results in a
decrease in TG, there are still important questions that need to be answered before
practitioners can safely recommend them to their patients. Future large RCTs need to
focus on ω-3 fatty acid supplementation in approximate doses of 4 g/d in women and
minorities with high TG levels since insufficient evidence exists to support practice
recommendations in these groups. Future studies should stratify by types of
hyperlipidemia to control for LDL and TC since ω-3 fatty acids have differential effects
based on the hyperlipidemia classification.
Conclusion
All of the recent studies (1994-2003) that evaluated the effect of long-chain ω-3
fatty acids on hypertriglyceridemia have methodological flaws. None performed a power
analysis before recruiting participants, which resulted in underpowered studies. There
was no control for confounding variables such as dietary intake of ω-3 fatty acids, no
report on double blind assessment of outcomes, and no intention to treat analysis. The
absence of these critical elements made it difficult to draw a conclusion about the
efficacy of the use of long-chain ω-3 fatty acids in the treatment of hypertriglyceridemia.
The Consolidated Standards of Reporting Trials (CONSORT) guidelines should be
followed as future studies are developed to improve study reporting (Moher, Schulz, &
Altman, 2001). Although the evidence supporting the use of long-chain ω-3 fatty acids in
the secondary prevention of hypertriglyceridemia is fairly strong, until there are larger
RCTs with longer durations the authors cannot recommend the use of long-chain ω-3
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Table 1. Boyack and Lookinland Methodological Quality Index
Possible
Points
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

Item
Score

Methods :
Multi-center/multi-national study
a. Yes
b. No

2
0

____

Study funded by drug company:
a. No
b. Yes/Not stated

1
0

____

Eligibility criteria:
a. Included all eligible subjects with # excluded/reasons given
b. # excluded or reasons for failure/exclusion not explicitly given
c. Selected patients/eligibility not described

2
1
0

____

Power analysis:
a. Power of 80% or greater and achieved sample size
b. Underpowered due to loss of follow-up
c. Power analysis not done

4
1
0

____

Sample equivalency addressed:
a. Yes
b. Addressed but no p value given
b. No

2
1
0

____

Randomization:
a. Use of random numbers table
b. Other method used
c. Not reported

2
1
0

____

Method of blinding subjects to treatment reported:
a. Yes
b. Stated but unclear
c. No

2
1
0

____

Blind assessment of outcome:
a. Yes
b. Partial
c. No

3
1
0

____

Concealment of treatment schedule:
a. Adequately concealed
b. Inadequate concealed/Unclear

4
0

____

Intention to treat analysis
a. Yes
b. No

2
0

____

Treatment arm differences:
a. Placebo and 1 parallel treatment
b. Placebo or parallel treatment only

2
1

____

SubTotal

Total/%
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Possible
Points
12.

13.

Item
Score

Duration of therapy:
a. ≥ 3 years
b. ≥ 2 years
c. ≥ 1 yr
d. ≥ 6 months
e. < 6 months

4
3
2
1
0

____

Intervention:
a. Dosing regimen (frequency/dose) explicitly described
1. Yes
2. No

1
0

____

1
0
N/A

____

3
1
0

____

3
2
1
0
N/A

____

Adherence to protocol reported:
a. Yes
b. No

1
0

____

Long term health outcome reported:
a. Yes
c. No

4
0

____

Statistical methods reported:
a. Yes
b. No

3
0

____

Major endpoints reported:
a. Stat significant/negative findings (sufficient power) >50% variables
b. Trend toward significance (sufficient power)
c. Negative findings (insufficient power)

2
1
0

____

Findings of adverse effects reported:
a. Significant difference (p value) between treatment and control group
b. Adverse effects only without p value addressed
c. Not reported

2
1
0

____

b. Explicit description of co-intervention
1. Yes
2. No
3. Not applicable
Outcomes:
14.

15.

16.

17.

Lost to follow up:
a. > 80% follow up in each group
b. Less than 80% follow up
c. Subjects not accounted for
Withdrawals reported individually by group:
a. Described # and reasons for withdrawal
b. Described either number or reason for withdrawal
c. Described withdrawals globally but not by group
d. Described neither number nor reason for withdrawal
e. Not applicable

Treatment Effect:
18.

19.

20.

SubTotal

Total/%
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Possible
Points
21.

22.

23.

Confidence interval between means of treatment groups reported:
a. Yes
b. No
Range of CI
a. If using mean diff/proportions, includes value of 0
1. No
2. Yes
3. Not applicable
OR
b. If using OR or RR, includes value of 1
1. No
2. Yes
3. Not applicable
Magnitude of reported differences:
Effect size
a. Large (>0.80)
b. Moderate (0.20 – 0.79)
c. Small (< 0.20)
d. Unable to calculate
OR
Proportionate differences > 20%
a. Yes
b. Available on some variables
c. No or unable to calculate

24. Quantitative boundary explicit
a. Yes
b. No
c. Not applicable

25.

26.

Item
Score

3
0

____

3
0
N/A

____

3
0
N/A

____

4
2
1
0

____

4
2
0

____

4
0
N/A

____

Summary:
Statement of financial disclosure/competing interests
a. Yes
b. No

2
0

____

Limitations/biases reported:
a. Yes
b. Partially
b. No

2
1
0

____

SubTotal

Total/%

Treatment of Hypertriglyceridemia 22
Table 2. General Characteristics of Studies of Ω-3 Fatty Acids for Treatment of Hypertriglyceridemia
Author
Chan et al., 2003

Laidlaw et al.,
2003

Subjects
n=24

n=32

Duration
6 weeks

4 weeks

Exclusion Criteria
DM, apolipoprotein E2/E2
genotype, macroproteinuria,
creatinemia > 1.4 mg/dl,
hypothyroidism, abnormal liver
enzymes, alcohol consumption >
30 g/d, CVD, or medications or
agents that affect liver
metabolism
Consumption of fish, borage and
evening primrose oil

Patient Characteristics

Study Purpose/Outcomes

Obese males (waist
circumference > 39.4 in,
BMI >29)
TG > 106 mg/dL
TC > 200 mg/dL

To determine the efficacy of
Omacor in treating
dyslipidemia in obese men.

Females only
Mean age = 48 yrs
Mean weight = 150 lb
Mean BMI = 25.5

To determine the effects of
GLA, EPA, and DHA on
triglycerides, fatty acid
patterns, and serum
phospholipids.

Treatment

MQI

Omacor 3.4 g/d
(EPA + DHA)
vs. Corn oil

37%

4 g EPA + DHA
(4:0)
vs. 4 g EPA +
DHA and 1 g GLA
(4:1)
vs. 2 g GLA (4:2)
vs. 4 g GLA (4:3)

38%

↓ TG by 18%a
↓ VLDL 33%a

↓TG
39.7% (4:0)
39.2% (4:1)
35.4% (4:2) a
↓ LDL
11.3% (4:2)a
↑HDL
7% (4:0)
10% (4:1) a
↓ non-HDL TC
5.3% (4:1)
14.4% (4:2) a
↓ TC:HDL
11% (4:0)a
9.6% (4:1)a
14% (4:2)d
14.7% (4:4)a
↓ LDL:HDL
6% (4:1)a
14.8% (4:2)e
19.9% (4:4)a
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Calabresi et al.,
2000

Goodfellow et al.,
2000

Mori, et al., 2000

Borthwick, 1998

Grimsgaard et al.,
1997

n=14

n=30

n=56

n=55

n=234

8 weeks

16 weeks

6 weeks

12 weeks

7 weeks

Lp(a) concentration > 30 mg/dl,
apolipoprotein E2/E2 phenotype,
HRT, β-blockers, or diuretics.

Males & Females with
FCHL
Mean age = 47 yrs,
TC and/or TG > 90% than
the general population
Mean TG = 378 mg/dL
Not overweight
Low fat (30% calories) diet
≥ 6 months.

Active or recent ex-smoker, DM,
HTN, hx of coronary, cerebral,
or PV disease, HRT, taking
vasoactive medications,
vitamins, anti-oxidants, or fish
oils.

Males & Females
Age range = 38-69 yrs
TC > 250 mg/dL,
Low fat diet for 3 months

Symptomatic CHD within the
previous 3 months, DM, liver
and renal disease. NSAID,
antihypertensive, or lipid
therapy. Consumption of < 210
ml alcohol/wk.

Males
Age range = 20-65 yrs
BMI range = 25-30
Tc > 231 mg/dL
TG > 160 mg/dL

177 mg/dL ≥ TG ≥ 885 mg/dL,
TC≤ 200 mg/dL
Weight change > 2.2 lb/wk
Unstable lipid values

Males & Females
Mean age = 54 yrs
Mean weight = 170 lb.

Smokers, prescription or
nonprescription drug users, DM,
CV, liver and renal disease,
bleeding disorders, and
alcoholism.

Males
Age range = 35-55 yrs
TC < 367 mg/dL
TG < 442 mg/dL
Consumption of < 4 fish
dishes/ week

To determine the efficacy of
Omacor in lowering lipids
in patients with FCHL.
↓ TG 21% vs. placebo
↓ TG 27% vs. baseline a
↓ VLDL 29% vs. placebo
↓ VLDL 18% vs. baselinea
↑ LDL 25% vs. placebob
↑ LDL 21% vs. baselinel –
not significant
To determine the efficacy of
ω-3 fatty acids in treating
hypercholesterolemia and
improving large artery
endothelial function.
↓ TG 16%a
To determine the
differential effects of EPA
and DHA on lipids,
lipoproteins, glucose, and
insulin.
↓ TG 20% DHA groupj
↓TG 18.4% EPA groupk
↑ LDL 8% DHA groupi
To determine the effects of
Omacor on lipid value in
patients with
hyperlipidemia.
↓ TG 28%e
To determine the effects of
EPA and DHA on lipids,
apolipoproteins, and serum
phospholipid fatty acid
composition.
↓ TG 26% DHA groupc

Omacor 3.4 g/d
(EPA + DHA) in a
crossover trial

34%

K-85 (85% EPA &
DHA) + 4 IU Vit E
(Omacor) vs.
Corn oil

37%

EPA, 4 g/d vs.
DHA, 4 g/d vs.
Olive oil 4 g/d

32%

Omacor (4 g EPA
+ DHA/d) vs.
Corn oil 4g/d

42%

EPA, 4 g/d vs.
DHA, 4 g/d vs.
Corn oil, 4 g/d

54%
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Harris et al., 1997

Silva et al., 1996

Mackness et al.,
1994

n=42

n = 40

n=79

16 weeks

8 weeks

14 weeks

Cold water fish >1/week, Type
III hyperlipidemia, MI < 6 mo
before, ALT > 3x normal,
Fasting glucose > 200 mg/dL,
Creatinine > 2 mg/dL, Platelet
count < 60 x 109/l, Hemoglobin
< 10 g/dL, Pregnant, or breast
feeding, 2 alcohol drinks/d
Clinically significant disease

Males & Females
Age range = 18-75 yr
TG 492– 2000 mg/dL

Hypersensitivity to fish oil
Creatine > 1.5 mg/dL
Liver or non-atherosclerotic
neurologic diseases, DM, MI or
stroke ≤ 6 months ago
Heart failure, premenopause,
secondary hypercholesterolemia,
> 96 g alcohol/day

Males & Females
Age range = 18-70 yr
TG > 200 mg/dL or
Mixed hyperlipidemia with
TC > 200 mg/dL and
TG > 200 mg/dL

DM, hypothyroidism, serious
illness in the past 3 months,
severe concurrent illness, and
drug and alcohol abusers

Males & Females
Age range = 18-70 yrs
Primary type IIb or IV
hyperlipidemia
TG 177-885 mg/dL,
TC > 200 mg/dL

↓ TG 21% EPA groupd
↓ TC 2.5% EPA groupa
↑ HDL 4% DHA groupc
To determine the efficacy
and safety of Omacor in
treating patients with
hypertriglyceridemia.
↓ TG 45% e
↓ TC 15% c
↓ VLDL 32% e
↓ TC:HDL ratio 20% f
↑ LDL 32% h
↑ HDL 13 %g
To determine the efficacy of
ω-3 fatty acids and fish
consumption in the
treatment of Portuguese
patients with
hypertriglyceridemia and
mixed hyperlipidemia.

Omacor 4 g/d
(EPA + DHA) vs.
Corn oil

35%

Fish oil (EPA +
DHA, 3.6 g/d) vs.
Soya oil

26%

K-85 4g/d vs.
Corn oil 4 g/d

29%

↓ TG 27.8% m - not
significant
To determine the efficacy of
K-85 in treating patients
with primary
hypertriglyceridemia.

↓ TG 28% c
↓ VLDL 24%d
↑ HDL 12%d
a
b
c
d
e
f
g
h
i
j
p < 0.05; p = 0.032; p < 0.001; p < 0.01; p < 0.0001; p = 0.0013; p = 0.014; p = 0.0014; p = 0.019; p = 0.003; k p = 0.012; l p = 0.054; m = 0.0867
DM = diabetes mellitus; CVD = cardiovascular disease; BMI = body mass index; TG = triglycerides; TC = total cholesterol; LDL = total low-density lipoprotein; VLDL
= total very-low-density lipoprotein; HDL = total high-density lipoprotein; EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; GLA = gamma-linolenic acid;
Lp(a) = lipoprotein a; FCHL = Familial combine hyperlipidemia; HRT = hormone replacement therapy; HTN = hypertension; PV = peripheral vascular, ALT = alanine
aminotransferase; MI = myocardial infarction

Treatment of Hypertriglyceridemia 25
Table 3. Types of Hyperlipidemia*
Type I hyperlipoproteinemia

A rare disorder characterized by high TG levels and
pancreatitis.

Type II hyperlipoproteinemia

Elevation of LDL by either primary or secondary
causes and low TG and VLDL concentrations.
Includes familial hypercholesterolemia, familial
combined hyperlipidemia, defective familial
apolipotrotein B, and polygenic
hypercholesterolemia.
Characteristic xanthomas and premature
atherosclerosis
Common in middle-aged men with a family history
of variable elevated triglycerides.

Type III, or
dysbetalipoproteinemia
Type IV
Type V

Secondary hypertriglyceridemia
Familial lecithin cholesterol
acyltransferase deficiency

*

A rare disorder distinguished by a faulty clearance of
exogenous and endogenous triglycerides which puts
the person at increased risk for life-threatening
pancreatitis.
Most common type; result of another health
condition.
A rare disorder that is a result of a deficient enzyme
manifested by severe hypercholesterolemia,
hyperphospholipidemia, and hypertriglyceridemia

Adapted from: Beers, M. H., & Berkow, R. (Eds.). (1999). The Merck Manual of
Diagnosis and Therapy (17th ed.). [On-line], Available:
http://www.merck.com/pubs/mmanual/
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Table 4. Sources of ω-3 Fatty Acids*
EPA + DHA content in a
3 oz serving
Pacific Herring
Sardines
Trout, farmed rainbow
Salmon, Atlantic, wild
Trout, wild rainbow
Tuna, white canned in water, drained
Halibut
Crab, Alaskan King
Mackerel
Shrimp, mixed species
Scallops
*

1.81 g
0.98-1.70 g
0.98 g
0.9-1.56 g
0.84 g
0.73 g
0.4-1.0 g
0.35 g
0.34-1.57 g
0.27 g
0.17 g

Amount needed for
≈ 1 g/d of EPA +
DHA
1.5 g
2-3 g
3g
2-3.5 g
3.5 g
4g
3-7.5 g
8.5 g
2.-8.5 g
11 g
17.5 g

Adapted from Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002). Fish
consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 106,
2747-2757.

